Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | UNG | P13051 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 7/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525964 | 0.90 | PKM (0.50) | NPC1RAB9AL3MBTL1PKMLMNA | |
| SCHEMBL1128464 | 0.80 | NR5A1 (0.63) | NPC1RAB9AUNGNR5A1FAAH | |
| SCHEMBL11470886 | 0.80 | NR5A1 (0.63) | NPC1RAB9AUNGNR5A1FAAH | |
| SCHEMBL8962079 | 0.80 | NR5A1 (0.63) | NPC1RAB9AUNGNR5A1FAAH | |
| SCHEMBL8324472 | 0.78 | NPC1 (0.64) | NPC1RAB9AL3MBTL1UNGNR5A1 | |
| SCHEMBL206523 | 0.78 | S1PR1 (0.53) | NPC1RAB9AL3MBTL1PKMLMNA | |
| SCHEMBL206623 | 0.77 | MAPT (0.51) | NPC1RAB9AL3MBTL1UNGALDH1A1 | |
| SCHEMBL207815 | 0.77 | MAPT (0.51) | NPC1RAB9AL3MBTL1UNGALDH1A1 | |
| SCHEMBL251286 | 0.77 | ALOX5 (0.52) | UNGNR5A1FAAH | |
| SCHEMBL206510 | 0.77 | CA12 (0.49) | NPC1RAB9AUNGCDC25BFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | NPC1 62/4885RAB9A 1357/4885L3MBTL1 479/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | NPC1 62/4885RAB9A 1357/4885L3MBTL1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.